Abstract
Background: Baricitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor, improved disease severity in adults with moderate-to-severe atopic dermatitis (AD) in multiple Phase 3 trials. The objective of this post-hoc analysis was to evaluate the impact of baseline body surface area (BSA) on clinical responses to baricitinib monotherapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
